{"id":50332,"date":"2020-05-22T19:12:44","date_gmt":"2020-05-22T17:12:44","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=50332"},"modified":"2020-05-22T19:16:42","modified_gmt":"2020-05-22T17:16:42","slug":"federfarma-spesa-farmaceutica-un-sistema-fallimentare-cosi-non-puo-andare-avanti","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/federfarma-spesa-farmaceutica-un-sistema-fallimentare-cosi-non-puo-andare-avanti\/","title":{"rendered":"Fedefarma. Pharmaceutical expenditure: A failed system. So it can't go on"},"content":{"rendered":"

Pharmaceutical expenditure: ancient vices require modern interventions<\/h2>\n

Federfarma \u2013 05\/22\/2020<\/a><\/p>\n

FEDERFARMA intervenes on the latest AIFA monitoring relating to 2019 pharmaceutical expenditure for \"\"<\/a>strongly highlight the urgent need to structure new models to remedy ancient ills.<\/p>\n

The data is once again unequivocal:<\/p>\n

While for last year pharmaceutical expenditure for direct purchases recorded an absolute deviation of over 2.6 billion euros compared to the imposed limit of 6.69% (with no Region capable of respecting the expenditure ceiling), the net agreed pharmaceutical expenditure paid by the NHS stood at 7.7 billion euros, showing a decrease of 16 million compared to 2018.\"\"<\/a><\/p>\n

A change of direction is therefore urgently needed, a different perspective that FEDERFARMA has always proposed with strength and determination in all venues, aware of the fact that a priori criticisms are of little use if not accompanied by concrete and feasible proposals, to be necessarily agreed between institutional decision makers and industry stakeholders.<\/p>\n

It is useless to continue to plead the goodness of an organizational model, in fact bankruptcy, which places as the fulcrum of the system not the patient but the administrative centralization of expenditure as if it were the panacea for all ills.
\nIt is useless to cling to the by now ancient "excuse" that the overruns of direct pharmaceutical expenditure are due to the introduction of innovative drugs, financed with special funds.<\/p>\n

\"\"<\/a>It is useless to continue to humiliate the professional figure of the pharmacist by emptying the pharmacy of medicines and increasingly limiting the "dispensing on behalf" of medicines to the advantage of direct distribution. This, unfortunately, is the best way to transform the pharmacy into a drug store on the US model. The Federation's efforts to professionalize the figure of the pharmacist must have been in vain, but the public initiatives to finance the modern community pharmacy will have been equally vain.<\/p>\n

What is needed to structure a modern expenditure control model is, conversely, an effective monitoring system: only the acquisition and punctual appreciation of data will be able to represent the critical points of the entire sector, allowing to intervene effectively.<\/p>\n

Some concrete proposals:<\/p>\n